תבנית:תרופה/אונגלייזה 5 מ"ג - Onglyza 5 mg

Monotherapy: Onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.Onglyza should not be used in patients with ESRDCombination therapy: Add-on combination: Onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (TZD), or a sulfonylurea (SU), when the single agent alone, with diet and exercise, does not provide adequate glycemic control.Initial combination: Onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate.Onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. In combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.